Cancer biotech CARGO Therapeutics (CRGX) priced its IPO at $15.00 – the low end of the $15.00-to-$17.00 price range – on Thursday night, Nov. 9, 2023. The cancer cell therapy company priced 18.75 million shares – the number of shares in the prospectus – at $15.00 to raise $281.25 million. That’s $18.75 million less than the estimated IPO proceeds of $300.0 million, which assumed that the IPO would price at the $16.00 mid-point of its range.
J.P. Morgan, Jefferies, TD Cowen and Truist Securities were the joint book-runners.
CARGO Therapeutics’ stock opened at $15.45 – up 45 cents or 3 percent from its IPO price – at 12:38 p.m. EST today – Friday, Nov. 10, 2023 – on the NASDAQ. Volume: 780,163 shares.
By the closing bell, CARGO Therapeutics’ stock had given up its modest opening-day gains to end at $14.53 – down 47 cents or 3.13 percent.
CARGO Therapeutics, based in San Mateo, California, is evaluating CRG-022, its lead CD22 CAR T-cell product candidate, in “a potentially pivotal Phase 2 clinical trial in patients with LBCL (large B-cell lymphoma) whose disease relapsed or was refractory to CD19 CAR T-cell therapy,” the prospectus says.
CARGO Therapeutics licensed the underlying CAR (chimeric antigen receptor) exclusively from the National Cancer Institute. A CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. CARGO Therapeutics’ potential cell therapy uses a cancer patient’s own cells, the prospectus says.
Principal shareholders include Samsara BioCapital and Third Rock Ventures.
CARGO Therapeutics is not profitable. For the 12 months that ended June 30, 2023, CARGO Therapeutics reported a net loss o f $56.63 million on no revenue.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on IPOScoop.com’s website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.